What is actually going on with Medvi right now?

As of April 2026, the FDA has issued a warning letter about marketing language on Medvi's website around compounded GLP-1 products. The company is also facing active class action lawsuits, most of them about advertising practices like spam email and unsolicited texts, and one broader case that raises questions about a specific compounded oral tirzepatide tablet sold through the company's pharmacy and clinical partners. Medvi has publicly disputed some of the claims. The regulatory process and the court cases are still open, so the picture is still forming.

Does compounded mean unsafe?

No. Compounded GLP-1 medications from licensed 503A and 503B pharmacies are a legitimate option prepared under federal and state rules. The current regulatory attention is about marketing language and supply chain transparency, not about compounding as a category. A trustworthy telehealth provider will name the pharmacy, explain that the product is compounded and not FDA-approved, and let you verify the pharmacy's credentials.

How do I know if a telehealth clinician is real?

You may not be matched with your specific clinician until after you complete your intake, which is normal. Once you are matched, ask for the clinician's name and licensed state, and then look them up in a state medical or nursing board database. If the clinician will not provide that, or the name does not come up anywhere, that is a fair reason to pause.

Where can I compare providers that share more of this information up front?

The GLP Winner provider survey matches you with options that publish clinician credentials, pharmacy details, and pricing transparently. You can also browse the GLP Winner insights hub for more on pricing, compounding, and how telehealth subscriptions work.

The Medvi Story and Safer Telehealth Shopping

Q: Did the FDA say Medvi's products are unsafe?

No. The FDA's warning letter was about how products were described in marketing, not a finding that products were unsafe or that patients had been harmed. The agency's concerns centered on language that implied a compounded product was the same as an FDA-approved brand and on labeling that could be read as suggesting Medvi itself was the compounder. Separate allegations about one specific compounded oral tablet are part of a private lawsuit, not an FDA finding.

Medvi is the fast-growing telehealth company built almost entirely on AI, and it is now the subject of FDA warning letters about marketing language and active class action lawsuits over advertising practices. The story is worth walking through carefully, and it offers a useful lens on the questions worth asking when you look at any telehealth provider.

Who This Helps

This one is for you if you have been seeing Medvi ads on Facebook or Instagram, read the glossy founder profile, or are curious what the regulatory and legal stories are actually about. It is also for anyone comparing telehealth providers and wanting a clearer picture of how today's online marketing works.

Why You Are Hearing About Medvi Right Now

One brother launched Medvi in September 2024 with around $20,000 and a stack of AI tools, and within a year had invited his brother to join and they were reporting more than $400M in revenue and serving hundreds of thousands of customers (The Nation). Instead of hiring a large team, they used AI to write code, build the website, generate marketing, and handle much of the customer service. On April 2, 2026, the New York Times ran a feature on the company treating it as the first clear example of a billion-dollar business run by almost no people (New York Times), and Forbes and other outlets published similar pieces in the same week. It was the kind of story that gets emailed around: two people, a little bit of money, a lot of AI, a reported $1.8B valuation trajectory.

What most of those profiles did not mention is that while they were going to press, the FDA had already sent Medvi a formal warning letter, and several lawsuits were in motion. The glossy narrative and the regulatory pushback were running on the same clock, just in different newsrooms.

What the Regulatory Trouble Is Actually About

It helps to separate two different things that often get blurred together: what was wrong with the website, and what that does or does not say about patient safety.

On February 20, 2026, the FDA sent warning letters to 30 telehealth companies, Medvi among them, about marketing language on their websites around compounded GLP-1 products (FDA, The Hill). The specific concerns in the letter to Medvi were about language that implied a compounded product was "the same as" an FDA-approved drug like Wegovy or Ozempic, and about product labels that used the Medvi brand name in a way that could suggest Medvi itself was the compounder (FDA Warning Letter). This was a marketing and labeling issue. It was not the FDA concluding that the products shipped to patients were unsafe or that patients had been harmed. The agency's push is toward clearer, more accurate descriptions of what is compounded and who prepares it.

Medvi has publicly pushed back on parts of the warning letter, arguing that the cited website was run by an affiliate marketing agency and that the flagged language has been corrected. The company's founder also said he would prohibit AI-generated fake-doctor advertising going forward (Futurism).

The lawsuits sit in a similar place. A class action filed in March 2026 is about marketing practices, specifically an allegation that affiliate channels send over 100,000 spam emails a year with spoofed headers to get past filters (Justia). A separate case from late 2025 is about unsolicited text advertising for weight loss medications (Justia). A broader racketeering-style class action against Medvi's pharmacy and clinical partners is different in nature; it alleges that a specific compounded oral tirzepatide tablet sold through the network does not have a demonstrated way to deliver the active compound in the body (FierceHealthcare). That third case is the only one that touches on product efficacy. All three are allegations at this stage, not rulings.

Alongside the regulatory and court filings, The Nation documented that the company was running around 800 Facebook accounts posing as individual doctors, with AI-generated profile photos (The Nation), and follow-on reporting noted AI-generated "before and after" weight loss images in Medvi ads that did not correspond to real patients (Drug Discovery & Development).

What this means for you: The current Medvi story is largely a marketing story. The FDA concern is about how products were described, not a finding that products were unsafe. The lawsuits are mostly about advertising practices, with one case that also raises questions about one specific compounded product's efficacy. All of this is still being worked out by the agency and the courts, and the picture is likely to keep shifting.

How AI Changed Telehealth Advertising

Medvi is a vivid example of a broader shift. Telehealth marketing has leaned on AI in three places that matter to you as a shopper, and each one has drawn its own kind of scrutiny.

The most visible is the faces in the ads. AI can now generate a photo of a doctor, a patient, or a before and after in seconds, and that has fueled a wave of ads that look human but are not. In December 2025, a bipartisan group of 35 state attorneys general wrote to Meta asking the company to take down misleading AI-generated weight loss ads on Facebook and Instagram (NC DOJ), a signal of how widespread the pattern has become.

The copy on many telehealth sites is now written by AI, which is fine on its own, but AI copy drifts easily into language the FDA has said cannot be used for non-FDA-approved compounded products, like calling a compounded medication "the same as" a brand drug. Support experiences have also moved to chatbots, and while many work well, others misquote prices, miss cancellations, and keep charging cards customers thought were turned off. The FTC's 2025 case against telehealth company NextMed called out precisely those kinds of failures when it finalized a $150,000 penalty and ordered clearer disclosures up front (FTC).

The practical lesson is not that AI in telehealth is automatically a problem. It is that the guardrails around AI copy, AI images, and AI support are still catching up, so a little extra attention on your end makes a real difference.

What a Steady Telehealth Provider Looks Like

You can learn a lot about a telehealth provider in ten minutes of poking around the website. A few things to look for:

A real, licensed clinician matched to you as a patient. That person should be named to you at your consultation, licensed in your state, and findable in a state medical or nursing board database (Federation of State Medical Boards). Be cautious if the site relies heavily on stock medical imagery to build trust without giving you any way to verify the clinician you will actually see.
Clear pricing before you enter card details. The monthly cost, shipping, and any consultation or lab fee should be visible to you before you put your payment information in.
Plain language about what is being prescribed. If the product is compounded, the site should say so, name whether a 503A community compounding pharmacy or a 503B outsourcing facility fills it, and note that compounded products are not FDA-approved finished drugs (FDA Compounding Q&A).
A cancellation path that matches how easy it was to sign up. If subscribing took two clicks and canceling takes a phone call and a two-week notice, that is a signal.
A privacy policy you can read. Your name, address, and health information should not be quietly sold to ad platforms. The FTC has filed proposed orders against Cerebral in 2024, alleging improper disclosure of sensitive health data to advertising tools (FTC) and reached a $1.5M settlement with GoodRx on related allegations in 2023 (FTC). Those are allegations and settlements, not findings of guilt, but they show the agency is paying attention to this area.

GLP Winner exists to help with exactly this part of the process. The GLP Winner provider survey matches you with providers who publish a lot of this information up front, and if any of the details are hard to pin down on a specific site, the insights hub can help you get to the bottom of what you are looking at.

Red Flags Worth a Second Look

Patterns that keep showing up in the telehealth stories drawing FDA, FTC, and state attorney general attention:

Before and after photos that feel unrealistic. Many legitimate providers share success stories with a first name only to protect patient identity, so limited patient details are not a flag on their own. The flag is when the images look too perfect, show visually impossible changes, or are paired with dramatic weight loss numbers without any clinical context. Expect more regulator attention on what counts as an honest before and after in the coming months.
Claims that a compounded product is "the same as" or "equivalent to" a brand drug. The FDA has said these equivalence claims cannot be used in marketing for non-FDA-approved compounded GLP-1 products (FDA).
Media mentions that seem too good to be true. If a site is touting coverage from major outlets, you can verify by asking the company for a link to the article or video. Reputable providers will happily send it; GLP Winner lists every mention with the link for that reason.
Cancellation that is much harder than sign-up. The FTC's NextMed action called this out directly (FTC).
Aggressive email blasts or texts you never signed up for, and that do not stop even after you hit unsubscribe, especially ones that slip past your spam filter or use a sender address you do not recognize.

A single flag is not a verdict. A stack of them on the same site is a fair reason to slow down and compare what other providers are offering.

Questions to Ask Before You Sign Up

A good provider answers these clearly. A company may not match you with your specific clinician until after payment is processed, but the site should be transparent from the start about the team you will be meeting with and their credentials.

Who prescribes my medication, and what are their qualifications and state licensure?
Am I getting an FDA-approved brand like Ozempic, Wegovy, Mounjaro, or Zepbound, or a compounded GLP-1 product?
If compounded, which pharmacy fills it, and is it a 503A community pharmacy or a 503B outsourcing facility?
What is the full monthly cost, including consults, shipping, and labs, before I enter my card?
How do I cancel, and how fast does the charge stop after I do?
How is my health information used, and is any of it shared with advertising platforms?

What About Compounded GLP-1 Medications?

Worth being plain about. Compounded GLP-1 medications are a legitimate option that a doctor and a patient may choose together. They are prepared by licensed compounding pharmacies under two federal frameworks. 503A pharmacies are state-licensed and compound medications for individual prescriptions. 503B outsourcing facilities are registered with the FDA and follow FDA manufacturing standards (FDA Compounding Q&A). The GLP Winner article on 503A vs 503B compounding pharmacies walks through the difference.

The FDA's warning letters were about how compounded products were marketed, not about compounding itself. The agency told companies they cannot promote compounded products as equivalent to FDA-approved drugs. That shift toward clearer, plainer language benefits you because you end up with a more accurate picture of what you are buying.

Where Medvi Fits on GLP Winner

A quick, honest note on how we handle this. We are not partnered with Medvi, and they do not appear as an option when you get matched with providers on GLP Winner. Every provider on our results page goes through a verification process before being added, and Medvi has not been added through that process. What they do have is a community page on our site where you can read patient reviews and share your own experience. We carry that page for transparency and research, not as an endorsement, so you have a place to look things up and compare notes with other patients.

The harder truth is that patterns like the ones Medvi is facing are often invisible from the outside until a regulator or a reporter turns over the right rock. That is true across telehealth, not unique to one company. Most patients do not have the time or resources to dig into federal dockets, warning letter databases, and court filings before signing up for a subscription. What a comparison site can reasonably do is watch carefully, take it seriously when real issues surface, and adjust what it surfaces to you.

In Medvi's case, they are not in our active pricing comparison and not in our matched provider results. The community page stays live so you can read and share patient experiences, and we revisit how we feature providers as new information comes to light.

Final Takeaway

The Medvi story is a useful window into how fast-moving, AI-heavy telehealth marketing actually works, and what questions are worth asking before you choose any provider. The regulatory and legal picture is still forming, and most of what is on the table right now is about marketing language, advertising practices, and product descriptions, not about product safety findings. That distinction matters. What also matters is the simple version of what you are looking for in any telehealth provider: a real licensed clinician matched to you, a clear price before you pay, a straight explanation of what is being prescribed, a cancellation path that matches the sign-up experience, and a privacy policy that treats your health information with care. Those basics carry almost all of the weight.

If you enjoy posts like these, you can subscribe to receive newsletter updates.

The Medvi Story and What It Says About Telehealth Shopping

Who This Helps

Why You Are Hearing About Medvi Right Now

What the Regulatory Trouble Is Actually About

How AI Changed Telehealth Advertising

What a Steady Telehealth Provider Looks Like

Red Flags Worth a Second Look

Questions to Ask Before You Sign Up

What About Compounded GLP-1 Medications?

Where Medvi Fits on GLP Winner

Final Takeaway

Sources

Keep Reading

Do All Telehealth Providers Offer the Same GLP-1 Medications?

GLP-1 Access in 2026: What Telehealth Platforms Are Doing Differently Than a Year Ago

How to Evaluate Telehealth & Compounded GLP-1 Providers: Your Search Guide

Why GLP-1 Ads Are Changing: What the FDA's New Marketing Rules Mean for You

Categories

Curated by